CN101596156B - Compound sustained-release preparation for paracetamol and pseudoephedrine - Google Patents
Compound sustained-release preparation for paracetamol and pseudoephedrine Download PDFInfo
- Publication number
- CN101596156B CN101596156B CN2008101136982A CN200810113698A CN101596156B CN 101596156 B CN101596156 B CN 101596156B CN 2008101136982 A CN2008101136982 A CN 2008101136982A CN 200810113698 A CN200810113698 A CN 200810113698A CN 101596156 B CN101596156 B CN 101596156B
- Authority
- CN
- China
- Prior art keywords
- coating
- granule
- preparation
- standby
- gained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention relates to a sustained-release preparation taking paracetamol, pseudoephedrine or physiologically acceptable salt as active components. The sustained-release preparation is characterized in that a release system comprises a tablet core and/or a pill core and/or a coating which enables medicines to be slowly released, one part or all of the active components exist in the tablet core and/or the pill core, and the residual part of the active components exist in the coating.
Description
Technical field
The present invention relates to a kind of slow releasing preparation that is active component with acetaminophen, pseudoephedrine or its physiologically acceptable salt, belong to field of medicaments.
Background technology
Flu is the upper respiratory tract mucosa infection that is caused by a lot of dissimilar viruses, and its cardinal symptom often is nasal obstruction, sneeze, slight throat pain and heating etc., and systemic symptom has whole body discomfort, headache and myalgia etc.Because of no specific therapy can be sayed,, can only adopt symptomatic treatment to impel many remissions of flu so virus is firm then unnecessary.Because therefore the many symptoms that also do not have a kind of agents alleviate and deposit have various compound preparations to go on the market successively.These compound preparations select for use the medicine composition compound recipe of different curative effects to be used to alleviate simultaneous different symptoms.There is multiple symptom as patient,, then suits the medicine to the illness and use suitable compound preparation than more suitable with several individual event medicines, also more economical sometimes particularly at common cold initial stage.
Acetaminophen is an acetophenone amine dipron thing.By suppressing Cycloxygenase, improve the threshold of pain and produce analgesic activity, selectivity suppresses the synthetic of hypothalamus thermotaxic centre prostaglandin, cause peripheral blood vessel expansion, perspire and reach refrigeration function, its refrigeration function intensity is suitable with aspirin, but can generation with aspirin and contain the relevant side effect of aspirin product.By suppressing the synthetic of prostaglandin etc. and discharge, improve the threshold of pain and play analgesic activity, belong to the periphery analgesic, effect is than a little less than the aspirin, only to light, moderate pain is effective.This product does not have the obvious anti-inflammatory and anti effect.
Pseudoephedrine claims d-pseudephedrine again, is the optical isomer of ephedrine, and the two is by extracting gained in Herba Ephedrae or the ephedra equisetina grass, but synthetic at present.Pseudoephedrine discharges norepinephrine by stimulating SNE, play sympatheticomimetic action indirectly, its preventing respiratory is identical with the effect and the ephedrine of nasal congestion, but boosting only is 1/5 of an ephedrine, strengthening heart rate and pressor effect only is 1/4 of ephedrine, aspect the expansion bronchus smooth muscle only be its 1/2.The pseudoephedrine vasoconstrictive has certain selectivity, mainly shrinks the upper respiratory tract blood vessel and makes and breathe unobstructedly, is used to shrink nasal mucosa vessels alleviating the nasal obstruction symptom, and is evident in efficacy and side effect is little, in the use usually with its hydrochlorate or sulfate.
Acetaminophen, pseudoephedrine are prepared into slow releasing preparation, can overcome the relevant symptom of flu comprehensively, comprise simultaneously symptoms such as obturation with pain and heating, sneeze.Since acetyl aminophenol, pseudoephedrine using dosage, rate of release, and the difference of aspects such as absorbance need provide a kind of both releases, absorption to reach synchronously, so that better play synergistic compound preparation, reduces the medication number of times and makes things convenient for patient's medication.
Summary of the invention
The purpose of this invention is to provide and a kind ofly can overcome the relevant symptom of flu comprehensively, and all active component all are the compound preparation that slow release discharges.Technical solution of the present invention is as follows:
The slow releasing preparation that is active component with acetaminophen, pseudoephedrine or its physiologically acceptable salt of the present invention, comprise delivery system, described delivery system is made up of the label that drug slow is discharged and/or ball core and coating, part or all is present in described active component in label and/or the ball core, and the active component remainder is present in the coating.Described acetaminophen, pseudoephedrine or its physiologically acceptable salt all are slow release and discharge.Described " part ", can be one of in two kinds of active component or two, or one of in two kinds of active component or a part of two.Slow releasing preparation of the present invention in every single dosage unit, contains acetaminophen 10-1000mg, pseudoephedrine or its physiologically acceptable salt 5-90mg.As preferably, contain acetaminophen 200-1000mg in each dosage unit, pseudoephedrine or its physiologically acceptable salt 20-90mg.
The physiologically acceptable salt of pseudoephedrine of the present invention comprises acylate or inorganic acid salt, wherein is preferably hydrochlorate or sulfate.
As preferred version of the present invention, described acetaminophen release characteristic is: 1h (25-65%), 2h (55-85%), 4h (more than 80%), 8h (discharging fully).
As preferred version of the present invention, the release characteristic of described pseudoephedrine or its physiologically acceptable salt is: 1h (20-65%), 2h (42-85%), 4h (60-90%), 8h (being not less than 70%).
Label of the present invention and/or ball core can be by hydroxypropyl methylcellulose, polyvinylpyrrolidone, ethyl cellulose, methylcellulose, Hydroxypropyl Methylcellulose Phathalate, cellulose acetate-phthalate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, cellulose acetate, cellulose diacetate, Triafol T, hexadecanol, Rikemal B 200, stearic acid, glyceryl monostearate, Brazil wax, hydroxy methocel, polyvinyl alcohol, poly-phthalic acid vinyl acetate, polystyrene, carbopol, polrvinyl chloride, octadecanol, diethyl phthalate, dioctyl phthalate, Polyethylene Glycol, sodium alginate, chitosan, gelatin, Lac, pectin, guar gum, sucrose, lactose, starch, dextrin, Icing Sugar, low-substituted hydroxypropyl cellulose, cross linked polyvinyl pyrrolidone, cross-linking sodium carboxymethyl cellulose, mannitol, microcrystalline Cellulose, pregelatinized Starch, in the titanium dioxide one or more are made.
Coating material of the present invention, one or more in can being compared by ethyl cellulose, starch, Aquacoat, methylcellulose, cellulose acetate, acrylic resin, Opadry, Su Li are made.
Slow releasing preparation of the present invention as required, can be tablet, granule, pill, capsule, suspensoid etc.
Slow releasing preparation of the present invention as required, can add lubricant, and described lubricant can and month be hung in the pure magnesium sulfate one or more for magnesium stearate, micropowder silica gel, Pulvis Talci, hydrogenated vegetable oil, polyethylene glycols.
Slow releasing preparation of the present invention, can not only overcome the relevant symptom of flu comprehensively, the performance synergistic interaction effect of compound drugs, and the release of two kinds of active component of slow releasing preparation of the present invention, absorb and to reach synchronously, it obtains desired drug release behavior in vivo and in vitro.Such drug release behavior can reduce takes number of times (by original 4 times on the one reduce to a day twice, promptly take night and morning).Therefore this preparation has the advantages that the medication number of times is few, medicine slowly discharges in vivo, blood drug level is steady, fluctuation is little, bioavailability is high, safe.
The specific embodiment
By following examples the slow releasing preparation that is active component with acetaminophen, pseudoephedrine or its physiologically acceptable salt of the present invention is done further to specify, but not as limitation of the present invention.
Embodiment 1
Prescription:
| Acetaminophen | 325g |
| Pseudoephedrine hydrochloride | 90g |
| Hydroxypropyl methylcellulose E5 | 40g |
| Brazil wax | 15g |
| Microcrystalline Cellulose | 36g |
| 10% 30 POVIDONE K 30 BP/USP 30Aqueous solution | In right amount |
| Magnesium stearate | In right amount |
The coating prescription:
| Opadry | ?15g |
| Pure water | Add to 100ml |
Preparation method:
(1) particulate preparation hydroxypropyl methylcellulose E5, microcrystalline Cellulose are crossed 80 mesh sieves respectively, with the abundant mixing of equivalent incremental method, again with equivalent incremental method and acetaminophen, pseudoephedrine hydrochloride and Brazil wax mix homogeneously, with 10% 30 POVIDONE K 30 BP/USP
30Aqueous solution is a binding agent system soft material, 20 mesh sieve system wet granulars, and 60 ℃ of dryings, 20 mesh sieve granulate, standby.
(2) preparation of coating solution adds to Opadry in the pure water, and adds pure water to 100ml, stirs 1 hour, and is standby.
(3) get (1) granule and carry out coating, obtain coated granule.
(4) in (3) gained granule, add an amount of magnesium stearate, mix homogeneously, tabletting promptly gets tablet.
(5) in (1) gained granule, add an amount of magnesium stearate, mix homogeneously, tabletting is got (2) coating solution, is wrapped in outside the tablet, gets final product coated tablet.
(6) get (3) gained particle packing in the hungry area softgel shell, promptly get capsule.
(7) get (3) gained granule direct packaging, promptly get granule.
The release characteristic of active component is as shown in table 1 in the gained different dosage form.
The release characteristic of active component in table 1 different dosage form
Embodiment 2
Prescription:
| Acetaminophen | 500g |
| Pseudoephedrine hydrochloride | 60g |
| Hydroxypropyl methylcellulose K15 | 6g |
| Hydroxypropyl methylcellulose E6 | 75g |
| Microcrystalline Cellulose | 45g |
| 10% 30 POVIDONE K 30 BP/USP 30Aqueous solution | In right amount |
| Stearic acid | In right amount |
The coating prescription:
| Pseudoephedrine hydrochloride | 30g |
| Cellulose acetate | 70.5g |
| Water | An amount of to dissolving fully |
Preparation method:
(1) particulate preparation hydroxypropyl methylcellulose K15, hydroxypropyl methylcellulose E6, microcrystalline Cellulose are crossed 80 mesh sieves respectively, mix mixing, again with acetaminophen and pseudoephedrine hydrochloride mix homogeneously, with 10% 30 POVIDONE K 30 BP/USP
30Aqueous solution is a binding agent system soft material, 20 mesh sieve system wet granulars, and 60 ℃ of dryings, 20 mesh sieve granulate, standby.
(2) to get pseudoephedrine hydrochloride soluble in water in the preparation of coating solution, adds cellulose acetate, and mix homogeneously is standby.
(3) get (1) granule and carry out coating, obtain coated granule.
(4) in (3) gained granule, add an amount of stearic acid, mix homogeneously, tabletting promptly gets tablet.
(5) in (1) gained granule, add an amount of stearic acid, mix homogeneously, tabletting is got (2) coating solution, is wrapped in outside the tablet, gets final product coated tablet.
(6) get (3) gained particle packing in the hungry area softgel shell, promptly get capsule.
(7) get (3) gained granule direct packaging, promptly get granule.
The release characteristic of active component is as shown in table 2 in the gained different dosage form.
The release characteristic of active component in table 2 different dosage form
Embodiment 3
Prescription:
| Acetaminophen | 650g |
| Pseudoephedrine sulfate | 45g |
| Pregelatinized Starch | 110g |
| Carboxymethyl starch sodium | 20g |
| Hydroxypropyl methylcellulose K4 | 7g |
| Hydroxyethyl-cellulose | 72g |
| Microcrystalline Cellulose | 60g |
| Brazil wax | 50g |
| 10% 30 POVIDONE K 30 BP/USP 30Aqueous solution | In right amount |
| Pulvis Talci | 20g |
The coating prescription:
| Opadry II | 30g |
| Pure water | 1000ml |
Preparation method:
(1) each component is crossed 100 mesh sieves respectively in the prescription, and is standby;
(2) immediate-release granules preparation: with recipe quantity pregelatinized Starch, the abundant mixing of 1/2 amount carboxymethyl starch sodium, again with equivalent incremental method and acetaminophen mix homogeneously, with 10% 30 POVIDONE K 30 BP/USP
30Aqueous solution is a binding agent system soft material, 20 mesh sieve system wet granulars, and 60 ℃ of forced air dryings, 20 mesh sieve granulate add 1/2 amount carboxymethyl starch sodium, magnesium stearate mixing, measure intermediate content, and it is heavy to calculate slice;
(3) slow-releasing granules preparation: with the mixed powder of recipe quantity hydroxypropyl methylcellulose K4 and pregelatinized Starch, microcrystalline Cellulose with the abundant mixing of equivalent incremental method, again with equivalent incremental method and acetaminophen mix homogeneously, with 10% 30 POVIDONE K 30 BP/USP
30Aqueous solution is a binding agent system soft material, 20 mesh sieve system wet granulars, and 60 ℃ of forced air dryings, 20 mesh sieve granulate add the magnesium stearate mixing, measure intermediate content, and it is heavy to calculate slice;
(4) with microcrystalline Cellulose, Brazil wax, cross 80 mesh sieves respectively, mix mixing, again with the pseudoephedrine sulfate mix homogeneously, with 10% 30 POVIDONE K 30 BP/USP
30Aqueous solution is a binding agent system soft material, 20 mesh sieve system wet granulars, and 60 ℃ of dryings, 20 mesh sieve granulate add the magnesium stearate mixing, measure intermediate content, and it is heavy to calculate slice;
(5) above-mentioned three kinds of granules are suppressed three-layer tablet with the 20*9mm drift.
(6) preparation of coating solution adds to Opadry II 30g in the pure water, and adds pure water to 1000ml, stirs 1 hour.
(7) with the plain sheet of (5) gained, put to the coating machine, air blast is heated to about 50 ℃, at the uniform velocity sprays into the coating solution coating, and the limit sprays into the heating of coating solution snare drum wind, makes plain sheet temperature remain on 45-50 ℃, until evenly wrapping the thin film clothing, is drying to obtain.
The release characteristic of active component is as shown in table 3 in the resulting dosage forms.
The release characteristic of active component in table 3 different dosage form
Embodiment 4
Prescription:
| Acetaminophen | 325g |
| Pseudoephedrine sulfate | 90g |
| Celphere | 130g |
| Hydroxypropyl methylcellulose E5 | 6g |
| The Sulisi aqueous dispersion | 80g |
| The water solublity coating powder | 5g |
| Titanium dioxide | 5g |
| Stearic acid | 5g |
| 30 POVIDONE K 30 BP/USP 30 | In right amount |
| Water | In right amount |
| Dehydrated alcohol | In right amount |
| The moon is hung pure magnesium sulfate | In right amount |
The coating prescription:
| Opadry | 30g |
| Pure water | Add to 1000ml |
Preparation method:
(1) acetaminophen slow-release micro-pill preparation
I, an amount of 30 POVIDONE K 30 BP/USP 30 is added an amount of dehydrated alcohol be made into 5% (w/w) solution, standby;
II, stearic acid is added an amount of dehydrated alcohol be mixed with 5% (w/w) solution, standby;
III, get an amount of recipe quantity celphere and put in the coating pan;
IV, take by weighing the stearic acid ethanol solution for preparing and be sprayed on the celphere;
V, spray 30 POVIDONE K 30 BP/USP 30 ethanol solutions successively, the hydrojet intermission also adds acetaminophen, treats that acetaminophen adheres to the ball wicking surface and repeats said process again, finishes until adding powder;
VI, take out and to make micropill in 35 ℃ of dryings 12 hours;
VII, sieve with 14 mesh sieves and 20 orders.
Promptly get acetaminophen pastille micropill, standby.
(2) pseudoephedrine sulfate slow-release micro-pill
I, preparation 10%HPMC E5 aqueous solution, standby;
II, get the Sulisi aqueous dispersion and add water, shake up standby;
III, preparation contain the water solublity coating solution of water solublity coating powder 10%, titanium dioxide 1%;
IV, preparation 40% pseudoephedrine sulfate aqueous solution add above-mentioned HPMC solution again, stir evenly standby;
V, get the celphere coating, spray step IV gained solution is collected micropill to finishing;
VI, to pseudoephedrine sulfate micropill coating, spray into the Sulisi aqueous dispersion after, wrap the water solublity coating solution again.
Promptly get pseudoephedrine hydrochloride pastille micropill, standby.
(3) preparation of coating solution: 30g adds in the pure water with Opadry, and adds pure water to 100ml, stirs 1 hour.
(4) get (1), (2) micropill carries out coating, obtains coated granule.
(5) in (4) gained granule, add an amount of month pure magnesium sulfate of extension, mix homogeneously, tabletting promptly gets tablet.
(6) in (1), (2) gained micropill, add an amount of month pure magnesium sulfate of extension, mix homogeneously, tabletting is got (3) coating solution, is wrapped in outside the tablet, gets final product coated tablet.
(7) get (1), (2) gained particle packing in the hungry area softgel shell, promptly get capsule.
(8) get (1), (2) gained granule direct packaging, promptly get granule.
The release characteristic of active component is as shown in table 4 in the gained different dosage form.
The release characteristic of active component in table 4 different dosage form
Embodiment 5
Prescription:
| Acetaminophen | 325g |
| Pseudoephedrine hydrochloride | 90g |
| Celphere | 20g |
| Hydroxypropyl methylcellulose K 4 | 6g |
| Hydroxypropyl methylcellulose E5 | 7g |
| Microcrystalline Cellulose | 42g |
| Pregelatinized Starch | 21g |
| The Sulisi aqueous dispersion | 80g |
| Light water dissolubility coating powder | 5g |
| Titanium dioxide | 5g |
| 10% 30 POVIDONE K 30 BP/USP 30Aqueous solution | In right amount |
| Water | In right amount |
| Polyethylene Glycol | 3g |
| Dehydrated alcohol | In right amount |
The coating prescription:
| Opadry | In right amount |
| Pure water | Add to 1000ml |
Preparation method:
(1) the plain sheet preparation of acetaminophen slow release
With recipe quantity hydroxypropyl methylcellulose K
4With the mixed powder of pregelatinized Starch, microcrystalline Cellulose with the abundant mixing of equivalent incremental method, again with the acetaminophen mix homogeneously, with 10% 30 POVIDONE K 30 BP/USP
30Aqueous solution is a binding agent system soft material, 20 mesh sieve system wet granulars, and 60 ℃ of dryings, 20 mesh sieve granulate add the magnesium stearate mixing, tabletting, promptly;
(2) pseudoephedrine hydrochloride slow release micropill
I, preparation 10%HPMC E5 aqueous solution, standby;
II, get the Sulisi aqueous dispersion and add water, shake up standby;
III, preparation contain the water solublity coating solution of water solublity coating powder 10%, titanium dioxide 1%;
IV, preparation 40% pseudoephedrine hydrochloride aqueous solution add above-mentioned HPMC solution again, stir evenly standby;
V, get the celphere coating, spray step IV gained solution is collected micropill to finishing;
VI, to pseudoephedrine hydrochloride micropill coating, spray into the Sulisi aqueous dispersion after, wrap the water solublity coating solution again.
Promptly get pseudoephedrine hydrochloride medicine-feeding micropill, standby.
(3) Opadry is added in the pure water, and add pure water, stirred 1 hour to 100ml.
(4) get (2) gained micropill and add an amount of magnesium stearate, mix homogeneously, tabletting, compressed together with (1) gained sheet again, the plain sheet that makes is carried out coating, air blast is heated to about 50 ℃, at the uniform velocity spray into coating solution, make plain sheet temperature remain on 45-50 ℃,, be drying to obtain coated tablet until evenly wrapping the thin film clothing.
(5) the plain sheet that (1) is made is put to high-efficiency coating machine, is heated to about 50 ℃, at the uniform velocity sprays into the coating solution coating, makes plain sheet temperature remain on 45-50 ℃, until evenly wrapping the thin film clothing, is drying to obtain.
(6) get (5), (2) gained coated tablet, micropill fills in the hungry area softgel shell, promptly gets capsule.
The release characteristic of active component is as shown in table 5 in the gained different dosage form.
The release characteristic of active component in table 5 different dosage form
Claims (3)
1. compound slow release preparation is characterized in that:
Prescription:
The coating prescription:
Opadry 15g
Pure water adds to 100ml
And make by the following method:
(1) particulate preparation hydroxypropyl methylcellulose E5, microcrystalline Cellulose are crossed 80 mesh sieves respectively, with the abundant mixing of equivalent incremental method, again with equivalent incremental method and acetaminophen, pseudoephedrine hydrochloride and Brazil wax mix homogeneously, with 10% 30 POVIDONE K 30 BP/USP
30Aqueous solution is a binding agent system soft material, 20 mesh sieve system wet granulars, and 60 ℃ of dryings, 20 mesh sieve granulate, standby;
(2) preparation of coating solution adds to Opadry in the pure water, and adds pure water to 100ml, stirs 1 hour, and is standby;
(3) get (1) granule and carry out coating, obtain coated granule;
(4) in (3) gained granule, add an amount of magnesium stearate, mix homogeneously, tabletting promptly gets tablet; Perhaps in (1) gained granule, add an amount of magnesium stearate, mix homogeneously, tabletting is got (2) coating solution, is wrapped in outside the tablet, promptly gets coated tablet; Perhaps get (3) gained particle packing in the hungry area softgel shell, promptly get capsule; Perhaps get (3) gained granule direct packaging, promptly get granule.
2. compound slow release preparation is characterized in that:
Prescription:
The coating prescription:
Pseudoephedrine hydrochloride 30g
Cellulose acetate 70.5g
Water is an amount of to dissolving fully
And make by the following method:
(1) particulate preparation hydroxypropyl methylcellulose K15, hydroxypropyl methylcellulose E6, microcrystalline Cellulose are crossed 80 mesh sieves respectively, mix mixing, again with acetaminophen and pseudoephedrine hydrochloride mix homogeneously, with 10% 30 POVIDONE K 30 BP/USP
30Aqueous solution is a binding agent system soft material, 20 mesh sieve system wet granulars, and 60 ℃ of dryings, 20 mesh sieve granulate, standby;
(2) to get pseudoephedrine hydrochloride soluble in water in the preparation of coating solution, adds cellulose acetate, and mix homogeneously is standby;
(3) get (1) granule and carry out coating, obtain coated granule;
(4) in (3) gained granule, add an amount of stearic acid, mix homogeneously, tabletting promptly gets tablet; Perhaps in (1) gained granule, add an amount of stearic acid, mix homogeneously, tabletting is got (2) coating solution, is wrapped in outside the tablet, promptly gets coated tablet; Perhaps get (3) gained particle packing in the hungry area softgel shell, promptly get capsule; Perhaps get (3) gained granule direct packaging, promptly get granule.
3. compound slow release preparation is characterized in that:
Prescription:
The coating prescription:
Opadry 30g
Pure water adds to 1000ml
And make by the following method:
(1) acetaminophen slow-release micro-pill preparation
I, an amount of 30 POVIDONE K 30 BP/USP 30 is added that an amount of dehydrated alcohol is made into by w/w is 5% solution, standby;
II, stearic acid is added that an amount of dehydrated alcohol is mixed with by w/w is 5% solution, standby;
III, get an amount of recipe quantity celphere and put in the coating pan;
IV, take by weighing the stearic acid ethanol solution for preparing and be sprayed on the celphere;
V, spray 30 POVIDONE K 30 BP/USP 30 ethanol solutions successively, the hydrojet intermission also adds acetaminophen, treats that acetaminophen adheres to the ball wicking surface and repeats said process again, finishes until adding powder;
VI, take out and to make micropill in 35 ℃ of dryings 12 hours;
VII, sieve with 14 mesh sieves and 20 orders;
Promptly get acetaminophen pastille micropill, standby;
(2) pseudoephedrine sulfate slow-release micro-pill
I, preparation 10%HPMC E5 aqueous solution, standby;
II, get the Sulisi aqueous dispersion and add water, shake up standby;
III, preparation contain the water solublity coating solution of water solublity coating powder 10%, titanium dioxide 1%;
IV, preparation 40% pseudoephedrine sulfate aqueous solution add above-mentioned HPMC solution again, stir evenly standby;
V, get the celphere coating, spray step IV gained solution is collected micropill to finishing;
VI, to pseudoephedrine sulfate micropill coating, spray into the Sulisi aqueous dispersion after, wrap the water solublity coating solution again;
Promptly get pseudoephedrine hydrochloride pastille micropill, standby;
(3) preparation of coating solution: 30g adds in the pure water with Opadry, and adds pure water to 100ml, stirs 1 hour;
(4) get (1), (2) micropill carries out coating, obtains coated granule;
(5) in (4) gained granule, add an amount of month pure magnesium sulfate of extension, mix homogeneously, tabletting promptly gets tablet; Perhaps in (1), (2) gained micropill, add and hung pure magnesium sulfate in an amount of month, mix homogeneously, tabletting is got (3) coating solution, is wrapped in outside the tablet, promptly gets coated tablet; Perhaps get (1), (2) gained particle packing in the hungry area softgel shell, promptly get capsule; Perhaps get (1), (2) gained granule direct packaging, promptly get granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101136982A CN101596156B (en) | 2008-06-04 | 2008-06-04 | Compound sustained-release preparation for paracetamol and pseudoephedrine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101136982A CN101596156B (en) | 2008-06-04 | 2008-06-04 | Compound sustained-release preparation for paracetamol and pseudoephedrine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101596156A CN101596156A (en) | 2009-12-09 |
| CN101596156B true CN101596156B (en) | 2011-09-28 |
Family
ID=41417876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101136982A Expired - Fee Related CN101596156B (en) | 2008-06-04 | 2008-06-04 | Compound sustained-release preparation for paracetamol and pseudoephedrine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101596156B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476898A (en) * | 2002-08-23 | 2004-02-25 | 涛 吴 | Compound skeleton tablet capable of prolonging release after oral administrationi for curing common cold |
| CN1535686A (en) * | 2003-04-09 | 2004-10-13 | 北京德众万全药物技术开发有限公司 | Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method |
| CN1935142A (en) * | 2006-02-23 | 2007-03-28 | 北京阜康仁生物制药科技有限公司 | Slow-release capsule using noinclude, loratadine and pseudoephedrinesulfate as effective component, and its preparing method |
| CN1994278A (en) * | 2006-11-21 | 2007-07-11 | 北京润德康医药技术有限公司 | Sustained-release preparation using acetaminopher, desloratadine and pseudo ephedrine sulfat as active ingredients and preparation process thereof |
| CN101143138A (en) * | 2006-09-11 | 2008-03-19 | 上海玉安药业有限公司 | Paracetamol and pseudoephedrine hydrochloride tablets made by dry powder direct tabletting |
-
2008
- 2008-06-04 CN CN2008101136982A patent/CN101596156B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476898A (en) * | 2002-08-23 | 2004-02-25 | 涛 吴 | Compound skeleton tablet capable of prolonging release after oral administrationi for curing common cold |
| CN1535686A (en) * | 2003-04-09 | 2004-10-13 | 北京德众万全药物技术开发有限公司 | Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method |
| CN1935142A (en) * | 2006-02-23 | 2007-03-28 | 北京阜康仁生物制药科技有限公司 | Slow-release capsule using noinclude, loratadine and pseudoephedrinesulfate as effective component, and its preparing method |
| CN101143138A (en) * | 2006-09-11 | 2008-03-19 | 上海玉安药业有限公司 | Paracetamol and pseudoephedrine hydrochloride tablets made by dry powder direct tabletting |
| CN1994278A (en) * | 2006-11-21 | 2007-07-11 | 北京润德康医药技术有限公司 | Sustained-release preparation using acetaminopher, desloratadine and pseudo ephedrine sulfat as active ingredients and preparation process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101596156A (en) | 2009-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2225183T3 (en) | PHARMACEUTICAL FORMS OF CONTROLLED LIBERATION. | |
| JP6976946B2 (en) | A pharmaceutical composition containing an inhibitor of URAT1 having strong bioactivity. | |
| CN101987091A (en) | Venlafaxine hydrochloride sustained-release pellet capsules | |
| WO2021129735A1 (en) | Solid preparation, and preparation method therefor and use thereof | |
| CN104013592A (en) | Memantine hydrochloride slow-release pill and preparation method thereof | |
| CN103006612A (en) | Lisinopril controlled-release tablet and preparation method thereof | |
| KR20180135020A (en) | Oral Pharmaceutical Composition of Nicotinamide | |
| CN101658507B (en) | Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation | |
| CN101596158B (en) | Compound slow release preparation of acetyl aminophenol, pseudoephedrine and dextromethorphan | |
| CN105769773A (en) | Loxoprofen sodium sustained-release pellet | |
| CN101596156B (en) | Compound sustained-release preparation for paracetamol and pseudoephedrine | |
| CN101756981B (en) | Brufen loratadine pseudoephedrine release preparation and preparation method thereof | |
| CN1994278A (en) | Sustained-release preparation using acetaminopher, desloratadine and pseudo ephedrine sulfat as active ingredients and preparation process thereof | |
| CN1935142A (en) | Slow-release capsule using noinclude, loratadine and pseudoephedrinesulfate as effective component, and its preparing method | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN101947209A (en) | Divalproex sodium pellets and preparation method thereof | |
| CN1985823A (en) | Slow released preparation containing metformin hydrochloride and rosiglitazone and its preparing process | |
| CN101658521A (en) | Paracetamol, pseudoephedrine and chlorphenamine compound sustained release preparation | |
| CN101596157A (en) | The compound slow release preparation of a kind of pseudoephedrine, chlorphenamine and dextromethorphan | |
| CN101756987A (en) | Compound sustained-release preparation of guaiacol olycerin ether, pseudoephedrine and dextromethorphan | |
| CN101757001B (en) | Compound slow-release preparation of benorilate, pseudoephedrine and chlorphenamine | |
| CN101683340A (en) | Sustained-release preparation of compound metformin hydrochloride rosiglitazone and preparation method thereof | |
| CN1985819A (en) | Slow released preparation containing metformin hydrochloride and gliclazide and its preparing process | |
| CN101669918A (en) | Aspirin double-releasing preparation and preparation method thereof | |
| CN101756970A (en) | Sustained release preparation containing memantine hydrochloride and huperzine A and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 100083 Haidian District, Xueyuan Road, No. 30, A building, room No. 15, room, room 15 Patentee after: COSCI MED-TECH Co.,Ltd. Address before: 100190, room 1410, satellite building, No. 63, Zhichun Road, Beijing, Haidian District Patentee before: COSCI MED-TECH Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110928 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |